-
WHO Backs Regeneron Drug for COVID-19, Urges Action on Price Opens in a new window)
The health agency urged Regeneron, which holds the patent, to lower the drug’s price and work on equitable distribution worldwide. -
Congress Cites KHN Investigation in Probe of National Academies Opens in a new window)
Members of Congress want to ensure that reports from the national academies, chartered in 1863 to provide Congress with expert scientific advice, are widely accepted as independent and free from special-interest or financial influence.Comments
-
U.S. FDA Approves First Biosimilar Rival to Roche's Blockbuster Eye Drug Opens in a new window)
Biosimilars are cheaper versions of biologic drugs made from living organisms.Comments
-
ICER Releases Draft Evidence Report on Therapies for Severe Asthma
Tezepelumab for Severe AsthmaComments
-
Survey Finds People Won't Take Vaccine, But Will Take Drugs to Treat Covid
CNBC's Meg Tirrell joins Shep Smith to discuss Americans' attitude toward vaccines as well as treatments like monoclonal antibodies.Comments
-
Pioneering Gene Therapy Freed Her of Sickle Cell. Is a Cure at Hand? Opens in a new window)
Such treatments are extraordinarily promising and costly. Will the Biden administration commit to spending that could speed clinical trial results?Comments
-
How Ivermectin Became the Latest False Cure for the Coronavirus
Elevated by social media and right-wing pundits and politicians, ivermectin is not recommended by either the FDA or its manufacturer to treat covid-19.Comments
-
Cancer Drug Indications Remain on Labels Even After Trials Fail to Confirm Their Benefits Opens in a new window)
At issue is the accelerated approval program created nearly three decades ago to hasten availability of drugs for serious conditions with unmet medical needs.Comments
-
As Congress Considers Drug Price Reforms, Merck, Lilly and Takeda Execs Warn of Dire Consequences Opens in a new window)
As Congress reconvenes this month to resolve a $3.5 trillion budget package, Democrats are focused on enacting sweeping legislation that would allow the government to negotiate prices for prescription drugs.Comments
-
Wider Use of SGLT2 Inhibitors for CVD Recommended by NICE Opens in a new window)
NICE has updated its guidelines on the management of type 2 diabetes, recommending wider use of SGLT2 inhibitors in those with or at high-risk of cardiovascular disease (CVD).Comments
-
A Big Pharma CEO Is Battling Wall Street’s Most Feared Fund Opens in a new window)
GSK’s Emma Walmsley is seeking to survive a challenge from Elliott Investment Management, the activist that no CEO wants to hear from.Comments
-
Podcast: Pushing Against the QALY Criticism in Drug Pricing Opens in a new window)
QALY as a measurement has received a lot of criticism. It's been criticized in concept or in the specifics of how it's defined or used.Comments
-
Essex Baby Given £1.79M Drug Makes 'Huge Progress' Opens in a new window)
A baby who received the world's most expensive drug four weeks ago has made "huge" progress, his parents said.Comments
-
Cholesterol-Busting Drug Could Save Thousands of Lives
The health service will make the new treatment, inclisiran, available to 300,000 patients with high cholesterol and a history of cardiovascular disease over the next three years.Comments
-
EMA Lays Out Plans For Routine Use Of Real-World Evidence Opens in a new window)
A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year.Comments
Comments